Basic Information
ZOFRAN INJECTION 2 mg/ml
INJECTION
Regulatory Information
SIN05135P
October 16, 1990
Prescription Only
Therapeutic
INTRAVENOUS, INTRAMUSCULAR
August 10, 2023
June 3, 2025
XA04AA01
Company Information
NOVARTIS (SINGAPORE) PTE LTD
SANDOZ SINGAPORE PTE. LTD.
Active Ingredients
Strength: 2 mg/mL
Detailed Information
Contraindications
**CONTRAINDICATIONS** Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated (see section INTERACTIONS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Hypersensitivity to any components of the preparation (see sections WARNINGS AND PRECAUTIONS and ADVERSE DRUG REACTIONS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**INDICATIONS** **Adults** _ZOFRAN_ injection is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. _ZOFRAN_ is also indicated for the prevention and treatment of post-operative nausea and vomiting. **Paediatric Population** **Injection and oral formulations:** _ZOFRAN_ is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy. No studies have been conducted on the use of orally administered ondansetron in the prevention or treatment of post-operative nausea and vomiting; IV injection is recommended for this purpose.